Enliven Therapeutics, Inc. (ELVN)
Nasdaq · Healthcare · Biotechnology
$45.47−3.19%as of Oct 6, 2026, 4:35 AM ET
- Market cap
- $3.3B
- 52-week range
- $14.79 – $62.32
- 52-week change
- +131.38%
- EPS (trailing)
- −$1.67
- Analyst rating
- 1.2 Strong buy
- Next earnings
- Nov 11, 2026
Fiscal year to Dec 2025
- Net income
- −$104M
- Diluted EPS
- −$1.83
- Free cash flow
- −$70.5M
From the company’s annual report on SEC EDGAR.
About Enliven Therapeutics, Inc.
Enliven Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. Its clinical programs comprise ELVN-001, a small molecule kinase inhibitor which is in Phase 1 clinical trial to treat adults with chronic myeloid leukemia; and ELVN-002, a central nervous system (CNS) penetrant and irreversible human epidermal growth factor receptor 2 inhibitor that is in Phase 1 clinical trial for the treatment of non-small cell lung cancer (NSCLC) and other HER2 mutant tumors. The company was founded in 2019 and is headquartered in Boulder, Colorado.
Headquarters: Boulder, United States · 67 employees · enliventherapeutics.com